#voxilaprevir

[doctorfoxtor]

surprise bitch. bet you thought you'd seen the last of me

100 days of productivity

day 23

CVS/RS

AS has the worst prognosis when associated with LVD (AS+AR has a poor prognosis but not as bas as AS+LVD)

in acute mitral regurgitation, tachycardia actually reduces the volume of the regurgitant jet (so don't give BBs/CCBs)

PEFR specifically works as an indicator for large airway disease

acute pericarditis, normal kidney function = give NSAIDs AND colchicine for 3 months (colch reduces the duration of NSAID tx); sub steroids if not tolerated/not effective

coarcts are associated w/ bicuspid aorta, NF1 and berry aneurysms (and ofc Turner's)

atrial myxoma can cause PUO, afib, middiastolic murmur, clubbing

WPW assoc w/ MVP, Ebstein anomaly, HOCM and thyrotoxicosis

CNS

dorsal midbrain (medial longitudinal fasciculus) → vertical eye movements

Parinaud syndrome = MLF insult: paralysis of upward gaze with convergence-retraction nystagmus on attempted upward gaze, light-near dissociation aka pseudo-Argyll-Robertson pupils, eyelid retraction, preference for downward gaze in neutral position, papilloedema

statins may be associated with increased risk of secondary bleed in ischaemic stroke → commence statin after 48 hours after symptom onset

meningococcal meningitis: benzylpenicillin > III gen cephalosporin > chloramphenicol

for ischaemic stroke affecting the proximal anterior circulation ONLY, consider thrombectomy either alone (if between 6-24 hours after symptom onset, including wake-up strokes, AND if parenchyma is salvageable) or with thrombolysis (if confirmed within 4.5 hours of symptom onset); thrombectomy can also be considered in proximal posterior circulation strokes but not as strong evidence

Endocrine

to prevent refeeding syndrome, give at most 50% of caloric requirement in the first two days

to prevent adrenal insufficiency, pts on long term steroids should *double* their doses in periods of intercurrent illness

Rheum/Derm

Still disease: nonbiologics → anti-TNFs → anakinra → rituximab

Sjögren's → assoc w/ Raynaud's, RTA, sensory polyneuropathy

monomorphic papular rash without vesicles, cysts or comedones on chest and back (esp. after starting roids) = drug-induced acne; withdraw offending drug

DILE: skin and pleural involvement are common, with possible myalgia, arthralgia; nephritis very uncommon

AnkSpon: syndesmophytes = ossification of annulus fibrosus

Schober test → locate L5 on patient's back; mark one point 5 cm below L5 and one 10 cm above; measure the distance between the two points; ask patient to touch toes with knees straight; measure the distance between the two points; positive test <5 cm of increase in the distance (sign of AxSpA)

GIT

PSC: 75% are assoc w/ IBD (either occurring before or after intestinal symptoms); also, more than 20% proceed to develop cholangiocarcinoma

IBS + iron/calcium deficiency, especially worse during or after pregnancy → HUGE red flag for coeliac

s/p needlestick w/ confirmed HCV+ pt's fluids, do monthly HCV RNA testing, and the moment it turns positive, slam them w/ IFN+ribavirin OR sofosbuvir-velpatasvir-voxilaprevir; if done quickly enough, has a >90% likelihood of cure

ulcerative colitis → goblet cell depletion on biopsy is specific

Onc/Haem

vocal cord palsy due to nerve invasion is a contraindication to resection of a Pancoast or thyroid tumour

shelf lives of blood products: platelets = 5 days; RBCs = 4-5 weeks; cryoprecipitate/PCC/FFP = 2 years

cryoprec is used to replace fibrinogen, indicated when serum fibrinogen <0.15 g/dl

hu painful is it? → anti-Hu = painful sensory neuropathy ± cerebellar signs (SCLC, sometimes neuroblastoma)

reflexes like a yo-yo → anti-Yo = cerebellar signs (ca ovary, ca breast)

ripid eye movements → anti-Ri = opsoclonus-myoclonus (neuroblastoma***, ca breast, SCLC)

purkipheral neuropathy → anti-Purkinje cell = peripheral neuropathy (ca breast)

muscle riGADity → anti-GAD = diffuse hypertonia (ca breast, ca colon, SCLC)

Renal/Biochem/Toxo

activated charcoal may be useful in aspirin poisoning beyond the described 1-hr point as aspirin absorption actually slows down when ingested in large quantities and persists in the gut for a long time

peritoneal dialysis peritonitis → CoNS (esp S. epidermidis) > S. aureus

Immuno

Neutrophils Love Cheddar Cheese → neutrophil disorders are Leukocyte adhesion deficiency, Chédiak-Higashi, Chronic granulomatous disease

Some Call B-cells Brutal → B-cell disorders are Selective IgA deficiency, Common variable immunodeficiency, Bruton's agammaglobulinaemia

diGeorge is a pure T-cell disorder (that may in turn lead to secondary B-cell dysfunction)

BuT Her Son WAS Ataxic → combined B/T-cell disorders are Hypermacroglobulinaemia, Severe combined immunodeficiency, Wiskott-Aldrich Syndrome, Ataxia-telangiectasia

in immunocompromise, give abx for otherwise 'benign' conditions anyway (eg, mild Campylobacter diarrhoea in a pt taking biologics—tx as if severe w/ macrolide)

[marcioaugustoantoniassi]

Anvisa aprova novo medicamento para tratamento da hepatite C em adultos

Anvisa aprova novo medicamento para tratamento da hepatite C em adultos

Vosevi®, medicamento da farmacêutica Gilead Sciences, trata todos os genótipos de infecção crônica pelo vírus da hepatite C (HCV) em adultos com apenas um comprimido ao dia.

A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar o uso de Vosevi® (sofosbuvir/velpatasvir/voxilaprevir) da Gilead Sciences no Brasil. O medicamento é indicado para pacientes com infecção crônica pelo HCV,…

[databridgemarketresearchblog]

Hepatitis C Market 2020 Industry Research, Share, Trend, Industry Size, Price, Future Analysis, Regional Outlook to 2027 Research Report | DBMR Updates

This Hepatitis C Market research document predicts the size of the market with information on key vendor revenues, development of the industry by upstream & downstream, industry progress, key companies, along with type segment & market application. This market study takes into account a market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. Another major section of this Hepatitis C Market report is the competitive landscape which provides a clear insight into the market share analysis and actions of key industry players. Quality and transparency is strictly maintained while carrying out research studies to offer an exceptional market research document for your niche.

Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hepatitis-c-market

All the data of this market report is exceptionally useful to the clients and businesses for making decisions related to revenue, investment, import, export and consumption. To meet the strategic as well as specific needs of the organization or business, a comprehensive market research document such as this Hepatitis C Market report, has to be in place. Geographical scope of the products is also carried out comprehensively for the major global areas such as Asia, North America, South America, and Africa which helps define strategies for the product distribution in those areas. Competitive landscape is explored in terms of product range, strategies, and future prospects of the key players of the Healthcare industry.

Market Analysis: Besides target market information, DBMR also provides information about your competitor, your customers, products etc. A few techniques we use are: Customer analysis Competitor analysis Risk analysis Product research Advertising research E-mail survey and many more…

Hepatitis C market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned forecast period. Rising prevalence of hepatitis C worldwide and emerging markets are the factors responsible for the growth of this market.

The major players covered in the hepatitis C market are Abbvie Inc., Gilead Sciences Inc., Merck & Co., Inc., Bristol -Myers Squibb Company, F.Hoffmann-LA Roche Ltd., Biogen Inc., Schering Life Sciences., and Johnson and Johnson Services Inc, among others.

To Get This Report at an Attractive Cost, Click Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hepatitis-c-market

Market Analysis and Insights: Global Hepatitis C Market

Growing cases of chronic bloodborne infection drives the hepatitis C market. Due to increased cases of mistakenly inhaled illicit drugs, patients with HIV-AIDS, exposure to infected blood and family history with hepatitis C will boost up the hepatitis C market growth. Moreover, increased clinical trials and increased demand of antiviral drugs for the treatment of hepatitis C will boost up the global hepatitis C market. However, lack of patient’s awareness in developing countries and stringent FDA guidelines for the approval of new treatment or drugs may hamper the global hepatitis C market.

Hepatitis C is the viral infection that causes inflammation in the liver and sometimes not treated earlier may causes serious liver damage. Hepatitis C is transmitted through the infected blood of patients. Certain medical conditions such as HIV-AIDS, heavy alcohol use, toxin and some medication can develop hepatitis C infection which is causes by virus. Symptoms of Hepatitis includes hepatic encephalopathy, easily bleeding & bruising, fatigue, poor appetite, jaundice, dark-coloured urine, itchy skin, ascites, swallowing in legs. According to the survey report published by “Centers for Disease Control and Prevention” in 2016, 2.4 million peoples infected by the hepatitis C in the U.S.

This hepatitis C market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Hepatitis C Market Scope and Market Size

Hepatitis C market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel.

On the basis of type, the hepatitis C market is segmented into acute hepatitis C, chronic hepatitis C, and others

On the basis of diagnosis, the hepatitis C market is segmented into blood test, liver damage test and others

On the basis of treatment, the hepatitis C market is segmented medication, liver transplantation and others. Medication segment further divided into antiviral drugs and interferons

Route of administration segment of hepatitis C market is segmented into oral, parenteral and others

On the basis of end-users, the hepatitis C market is segmented into hospitals, specialty clinics and others

On the basis of distribution channel, the hepatitis C market has also been segmented into hospital pharmacy, retail pharmacy others

Key Developments for the Hepatitis C:

In 2017, AbbVie Inc., received the U.S. FDA approval of MAVYRET (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT 1-6) in as short as 8 weeks. Also, MAVYRET approved in European countries and japan. With this, the company has enhanced its  brand image in the market

In 2017, Gilead Sciences Inc., received approval in Canada for VOSEVI(Sofosbuvir/Velpatasvir/Voxilaprevir) for re-treatment of certain patients with chronic hepatitis C virus (HCV) infection. VOSEVI also approved in the United States, China, Singapore. With this approval, the company has enhanced its  brand image in the market

Hepatitis C Market Country Level Analysis

Hepatitis C market is analysed and market size information is provided by country, type, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hepatitis C market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, in Asia-Pacific, U.A.E, Saudi Arabia, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America holds the largest market share due to increased high prevalence of hepatitis and blood borne diseases. Europe is considered second largest market for hepatitis C due to increase in awareness about hepatitis in the region. Asia-Pacific is expected to account for the largest market share over coming years for the hepatitis C market due to high prevalence of HIV-AIDS & increased alcohol consumption and rapidly improving health care infrastructure in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Hepatitis C market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Hepatitis C Market Share Analysis

Hepatitis C market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hepatitis C market.

Customization Available: Global Hepatitis C Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-hepatitis-c-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail: Corporatesales@databridgemarketresearch.com

[dietasdicas1]

Anvisa aprova novo medicamento para tratamento da hepatite C em adultos

A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar o uso de Vosevi® (sofosbuvir/velpatasvir/voxilaprevir) da Gilead Sciences no Brasil. O medicamento é indicado para pacientes com infecção crônica pelo HCV, genótipos 1 a 6, sem cirrose ou com cirrose compensada, que falharam anteriormente na terapia com um regime antiviral de ação direta. O tratamento consiste em um regime simples de 12 semanas.

“Vosevi® chega para completar o portfólio da Hepatite C da Gilead no Brasil. Com isso, reforçamos nosso compromisso de levar terapias com altas taxas de cura para todos os pacientes infectados pelo HCV e também a nossa colaboração com

O Plano de Eliminação das Hepatites até 2030”, destaca a Dra. Rita Manzano Sarti, Diretora Médica da Gilead Sciences Brasil

A eficácia e segurança do Vosevi®, que faz parte da nova geração de tratamento em comprimido único ao dia da Gilead, foi estudada em 4 grandes ensaios clínicos de fase 3, chamado programa POLARIS. Os estudos POLARIS 1 e 4 foram desenhados para avaliar Vosevi® como terapia de resgate livre de ribavirina, atingindo RVS global de 97% (96% de RVS para resgatar pacientes expostos a um NS5A e 98% em expostos a um não-NS5A). Vosevi® foi bem tolerado, com perfil de segurança semelhante ao placebo.

A Hepatite C

A hepatite C é uma infecção causada pelo vírus da hepatite C (HCV), que possui pelo menos seis tipos (genótipos) distintos e que acomete preferencialmente o fígado, provocando uma inflamação que leva à formação de cicatrizes (fibrose hepática) e que, com o decorrer do tempo e sem um tratamento, pode levar à cirrose e ao câncer de fígado. Além do fígado, outros órgãos também podem ser acometidos.

A hepatite crônica C afeta aproximadamente 70 milhões de pessoas no mundo1. No Brasil, há uma estimativa de 700 mil portadores da doença2. Cerca de 155 mil foram diagnosticados entre 1999 e 2016 e há indícios de que ainda faltem 502 mil pessoas para serem diagnosticadas. Nesse período foram realizados 110 mil tratamentos, sendo 57 mil somente entre 2015 e 2017. Entre 2000 e 2015, foram identificados 46.314 óbitos relacionados à hepatite C. O fato é que grande parte das pessoas desconhece seu diagnóstico e poucos sabem como ocorreu a transmissão ou que exista tratamento para a doença.

Como ocorre a transmissão

O vírus da hepatite C é transmitido pelo contato com sangue infectado. Os principais meios de transmissão são reutilização e esterilização inadequada de equipamentos médicos, odontológicos e outros, compartilhamento de seringas e agulhas (como no uso de drogas ilícitas), práticas sexuais de risco e transmissão vertical (da mãe para o filho). Pessoas que receberam transfusão de sangue antes de 1993 também podem ter contraído a infecção.

A Hepatite C é a maior causa de cirrose, câncer de fígado e transplante hepático no mundo. Além das complicações relacionadas ao fígado, pode desencadear uma verdadeira doença sistêmica. Estudos comprovam que o vírus da Hepatite C aumenta os riscos do aparecimento de outras doenças como a Diabetes do tipo 2 e do Linfoma, por exemplo.

Número de pacientes com hepatite cresce 20% em dez anos no Brasil 

Foto: Shutterstock

Fonte: Gilead Sciences

Não se automedique, consulte um profissional de saúde.

googletag.cmd.push(function(){googletag.display(‘div-gpt-ad-1583864916328-0’)})

O post Anvisa aprova novo medicamento para tratamento da hepatite C em adultos apareceu primeiro em Guia da Farmácia.

O conteúdo Anvisa aprova novo medicamento para tratamento da hepatite C em adultos apareceu primeiro em Guia da Farmácia

from WordPress https://ift.tt/3bMNldl via IFTTT

[yuking2020]

new buy cas:1535212-07-7 1

采购(14)

采购 Voxilaprevir 1535212-07-7 1.1g 请有现货/做过的小窗我 谢谢 ————————- dinochem.com focused on the global chemicals markets

[expertofmarketinsights-blog]

Hepatitis C Drugs Market Estimated to Record Highest CAGR by 2026

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, sexually or from infected mother to fetus. Globally, hepatitis C virus exists in six distinct forms based on its genotypes amongst which Type 1 is the most common form representing around 60 -70 per cent of global infections. Click To Read More On Hepatitis C Drugs Market.

Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.

Get PDF Brochure of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1489

Hepatitis C drug market Driver

According to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C. This increasing prevalence of hepatitis C will drive growth of hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will further propel growth of hepatitis C drug market.

The governmental initiatives for patients to receive expanded drug coverage is also expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.

Hepatitis C Drug Market

The major players in hepatitis C drug market include Merck & Co. Inc., Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb.

Ask For Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1489

There are significant number of drugs available for Hepatitis C over the past few years and is expected to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline consists of dual as well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6. Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid patients.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[ahmednabel2289]

طرق علاج لفيروس C

التهاب الكبد الوبائي C

ينتج التهاب الكبد عن عدوى فيروسية عادةً، إلّا أنّ هناك أسباب أخرى محتملة لالتهاب الكبد، ومن هذه الأسباب التهاب الكبد المناعي الذاتي (بالإنجليزية: Autoimmune hepatitis) وذلك عندما ينتج الجسم أجساماً مضادة ضد أنسجة الكبد، والتهاب الكبد الذي يحدث كنتيجة ثانوية لتناول بعض الأدوية، والسموم، والكحول، وتُصنّف العدوى الفيروسية للكبد إلى خمسة أصناف رئيسية وهي التهاب الكبد A،B،C،D،E، وتختلف نظراً لاختلاف الفيروس المسبب لها، وينتقل التهاب الكبد C من خلال الاتصال المباشر مع سوائل الجسم للشخص المصاب، ويكون ذلك في أغلب الأحيان عن طريق استخدام الحقن الملوّثة بالفيروس أو الاتصال الجنسي.[١]

أحدث طرق لعلاج التهاب الكبد الوبائي C

في الحقيقة لا يوجد دواء واحد يناسب جميع المرضى بفيروس C، إذ إنّ هناك العديد من الأدوية المختلفة، أو الأنماط الجينية من التهاب الكبد C، وُيعدّ النوع الأول (بالإنجليزية: Type 1 hepatitis C) أكثر الأنواع شيوعاً، كما أنّ اختيار الدواء يعتمد أيضاً على مدى تليّف الكبد، وتتراوح مدّة العلاج من 8 إلى 24 أسبوعاً، ولكن في معظم الأحيان، تتمكّن الأدويةُ من إزالة الفيروس من الدم في غضون 12 أسبوعاً، وهذا ما يسمّى بالاستجابة الفيروسية المستدامة (بالإنجليزية: Sustained virologic response) واختصاراً (SVR)، وفيما يلي قائمة بأحدث الأدوية المستخدمة لعلاج التهاب الكبد من نوع C:[٢]

داكلاتاسفير (بالإنجليزية: Daclatasvir): يستخدم هذا الدواء لعلاج التهاب الكبد الفيروسي C من النوع الثالث، ويؤخذ على شكل أقراص مرة واحدة في اليوم إلى جانب دواء آخر يسمى سوفوسبوفير (بالإنجليزية: Sofosbuvir)، ومن آثار الداكلاتاسفير الجانبية المعاناة من الصداع أو الشعور بالتعب، كما أنّه قد يبطئ في بعض الأحيان من معدّل ضربات القلب، مما يستدعي استخدام جهاز تنظيم ضربات القلب.

إلباسفير/غرازوبريفير: (بالإنجليزية: Elbasvir/Grazoprevir) يُعدّ خياراً مناسباً للمرضى الذين يعانون من التهاب الكبد C، بالإضافة إلى تليف الكبد أو فيروس نقص المناعة البشرية، أو وصلوا إلى مرحلة متأخرة من أمراض الكلى، وغيرها من الأمراض التي يصعب علاجها، ويُؤخذ على شكل أقراص مرة واحدة يومياً لعلاج النوع الأول، والرابع، والسادس من التهاب الكبد الفيروسي C، ومن الآثار الجانبية التي قد يسبّبها الصداع الطفيف والشعور بالتعب.

غليكابريفير/بيبرنتاسفير: (بالإنجليزية: Glecaprevir/Pibrentasvir) يُستخدم هذا الدواء ثلاث مرات يومياً لعلاج جميع أنواع التهاب الكبد الفيروسي C، ومن الآثار الجانبية لهذا الدواء الصداع، والتعب، والإسهال، والغثيان.

ليديباسفير/سوفوسبوفير: (بالإنجليزية: Ledipasvir/Sofosbuvir) يُستخدم هذا الدواء على شكل حبوب مرة واحدة في اليوم لعلاج التهاب الكبد الفيروسي C من النوع الأول، والرابع، والخامس، والسادس، ومن آثاره الجانبية مشاكل في النوم، والشعور بالتعب، والصداع الطفيف، والإسهال.

أومبيتاسفير/باريتابريفير/ريتونافير: (بالإنجليزية: Ombitasvir/ Paritaprevir/Ritonavir) يُستخدم هذا الدواء لعلاج التهاب الكبد من النوع الرابع في حال عدم وجود تليف في الكبد، ويأتي على شكل حبوب تُؤخذ مرة واحدة يومياً، ومن آثاره الجانبية الشعور بالتعب، والضعف، ومشاكل النوم، والحكّة، واضطراب المعدة، كما أنّه قد يسبّب تلف الكبد الشديد في الأشخاص الذين يعانون من تليّف الكبد المتقدم، ولتعزيز فرصة الشفاء يمكن استخدام دواء آخر إلى جانب هذا الدواء يسمّى الريبافيرين (بالإنجليزية: Ribavirin).

أومبيتاسفير/باريتابريفير/ريتونافير مع داسابوفير: (بالإنجليزية: Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) يستخدم هذا العلاج للنوع الأول من التهاب الكبد، ومن آثاره الجانبية الحكة، والتعب، وصعوبة النوم، كما أنّه قد يسبّب تلف الكبد لدى الأشخاص الذين يعانون من تليّف الكبد المتقدم.

سيمبريفير (بالإنجليزية: Simeprevir) وسوفوسبوفير(بالإنجليزية: Sofosbuvir): يُستخدم هذان الدواءان معاً لعلاج النوع الأول من التهاب الكبد، ومن الآثار الجانبية لسوفوسبوفير صعوبة النوم، والتعب، والصداع، ومشاكل البطن، في حين يسبّب سيمبريفير الحكة، وجفاف الجلد، ويزيد الحساسية لأشعة الشمس.

سوفوسبوفير/فيلباتاسفير (بالإنجليزية: Sofosbuvir/Velpatasvir): يُستخدم هذا الدواء لعلاج جميع أنواع التهاب الكبد C، بأخذ قرص واحد يومياً، ومن آثاره الجانبية الشعور بالتعب والصداع.

سوفوسبوفير/فيلباتاسفير/فوكسيلابريفير (بالإنجليزية: Sofosbuvir/Velpatasvir/Voxilaprevir): يُستخدم هذا الدواء لعلاج جميع أنواع التهاب الكبد C، بأخذ قرص واحد يومياً في حال عدم الإصابة بتليّف الكبد وعدم فعالية العلاجات الأخرى لالتهاب الكبد، ومن آثاره الجانبية الصداع، والإسهال، والغثيان، والشعور بالتعب.

العلاج التقليدي التهاب الكبد الوبائي C

يتم علاج التهاب الكبد المزمن C باستخدام نوعين أساسين من الأدوية حتى وقت قريب نسبياً، وهما: إنترفيرون ألفا مديد المفعول (بالإنجليزية: Pegylated interferon) الذي يعمل علىتحفيز جهاز المناعة لمهاجمة الفيروس، والريبافيرين (بالإنجليزية: Ribaverin) الذي يمنع تكاثر الفيروس، والتي تمثل ظيفته الرئيسية، ويُؤخذ إنترفيرون ألفا مديد المفعول على شكل حقنة أسبوعياً لمدّة تصل في العادة إلى 48 أسبوعاً، وذلك اعتماداً على حالة المريض، أما الريبافيرين فيجب أن يُؤخذ إلى جانب إنترفيرون ألفا مديد المفعول، ويأتي على شكل كبسولات، أو أقراص، أو شراب، ويُؤخذ عن طريق الفم مرتين يومياً مع الطعام.[٣]

نصائح مهمة للمرضى

هناك بعض الأشياء التي يُنصح بها للمساعدة على الحد من الإصابة بتلف الكبد ومنع انتشار العدوى للآخرين، ومنها ما يلي:[٣][٤]

الالتزام بنظام غذائي صحيّ ومتوازن.

ممارسة التمارين الرياضة بانتظام.

الامتناع عن شرب الكحول.

التوقف عن التدخين.

عدم مشاركة الأشياء الشخصية، مثل فرشاة الأسنان أو شفرات الحلاقة مع الآخرين.

عدم مشاركة الإبر أو الحقن مع الآخرين.

الامتناع عن استخدام المخدرات، وخاصة تلك التي تُستخدم عن طريق الحقن.

توخي الحذر عند ثقب الجسم أو استخدام الوشم، وذلك بمعرفة كيفية تنظيف أدوات الثقب والوشم، وضرورة استخدام أدوات معقَّمة لكل شخص.

الابتعاد عن العلاقات الجنسية المتعددة المحرّمة.

from الرحلة http://bit.ly/2WYidzx via IFTTT

[amcrasto]

FDA approves Vosevi for Hepatitis C

FDA approves Vosevi for Hepatitis C

FDA approves Vosevi for Hepatitis C 07/18/2017 The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or…

[princeashy]

Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIV

Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIV

[ad_1]

A fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX, Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence, according to results of a new study presented…

[biomedres]

List of open access medical journal-BJSTR Journal

Treatment of Hepatitis C with Sofosbuvir, Velpatasvir and Voxilaprevir Decreases Hemoglobin A1c and Dependence on Anti-Glycemic Medications by  Kashif Aziz* in  Biomedical Journal of Scientific & Technical Research https://biomedres.us/fulltexts/BJSTR.MS.ID.001792.php

Aim: Hepatitis treatment with direct acting antivirals improves markers of diabetes like HbA1c and also decreases daily requirement of antidiabetic medications. Background: Insulin resistance and Type 2 diabetes are one of manifestation of Hepatitis C (HCV). It is proposed that circulating micro ribonucleic acid (miRNA) can do regulatory functions to modulate gene expression in peripheral tissues leading to insulin resistance and diabetes. Clearance of HCV with direct-acting antivirals (DAAs) significantly decreases hemoglobin A1c (HbA1c) and the dependence on anti-glycemic medications. Case Description: we present a case of HCV positive diabetic patient treated with the combination of sofosbuvir/velpatasvir/voxilaprevir, lead to improvement of his HbA1c as well as significant reduction of his daily insulin dose. Conclusion: It is concluded that treatment of HCV with DAAs may cause improvement of glucose metabolism and decreases dependence on anti-diabetic medications.

For more Articles on List of open access medical journal Please Click Here

For bjstr

Follow on Twitter : https://twitter.com/Biomedres01 Follow on Blogger : https://biomedres01.blogspot.com/ Like Our Pins On : https://www.pinterest.com/biomedres/

[daniablub]

Sofosbuvir-Velpatasvir-Voxilaprevir Effective in Previously Treated Chronic Hep C

Reuters Health Information from Medscape Medical News Headlines https://ift.tt/2y9mwRz via IFTTT

[liquidarea]

Epatite cronica C – Parere positivo del CHMP per la nuova combinazione Sofosbuvir/Velpatasvir/Voxilaprevir, trattamento per l’infezione cronica C

http://dlvr.it/PjcbmH

[dutifullyseverepenguin-blog]

Wir konzentrieren uns auf kundenspezifische Synthese organische Chemikalien, engagieren sich aktiv in F & E in allen Phasen und bieten Contract Research und Manufacturing Services (CRAMS) für globale Unternehmen in der pharmazeutischen Industrie. Kontaktieren Sie uns per info@pharma-china.com. FORSCHUNGSEINRICHTUNGEN Organisches Syntheselabor Analytisches Laboratorium Mikrobiologische Forschung und Testlabor Alle Produkte im Zusammenhang mit Patenten sind nur als F & E-Gebrauch zu liefern, keine kommerzielle Verkaufsvereinbarung. Www.pharm-china.com Hauptproduktliste sind als unten:

Product CAS No. Luliconazole CAS NO:187164-19-8 Dexlansoprazole CAS NO:138530-94-6 Pirfenidone CAS NO:53179-13-8 Isothipendyl hydrochloride CAS NO:1225-60-1 Tofacitinib citrate CAS NO: 540737-29-9   Vorapaxar Sulfate CAS No:705260-08-8 escitalopram oxalate CAS NO: 219861-08-2 Teneligliptin CAS NO: 760937-92-6 Dapagliflozin CAS No：461432-26-8 Dasatinib CAS No：302962-49-8 Linagliptin CAS No：668270-12-0 Canagliflozin hemihydrate CAS No：928672-86-0 Saxagliptin hydrochloride CAS No：709031-78-7 Saxagliptin hydrate CAS No：945667-22-1 Alogliptin benzoate CAS No：850649-62-6 Empagliflozin CAS No：864070-44-0 Ipragliflozin CAS No：761423-87-4 Ipragliflozin L-Proline CAS No：951382-34-6 Trelagliptin CAS No：865759-25-7 Omarigliptin CAS No：1226781-44-7 Sitagliptin CAS No：486460-32-6 Vildagliptin CAS No：274901-16-5 Ticagrelor CAS No：274693-27-5 Milrinone lactate CAS No：100286-97-3 Raltegravir potassiu CAS No：871038-72-1 Rivaroxaban CAS No：366789-02-8 Pitavastatin calcium CAS No：147526-32-7 Voxilaprevir CAS No：1535212-07-7 Ivabradine hydrochloride CAS No：148849-67-6 Silodosin CAS No：160970-54-7 Tasimelteon CAS No：609799-22-6 Lifitegrast CAS No：1025967-78-5 Sofosbuvir CAS No：1190307-88-0 Ledipasvir CAS No：1256388-51-8 Dapagliflozin propanediol CAS No：461432-26-8 Cobimetinib CAS No：934660-93-2 Huperzine A CAS No.：102518-79-6 Omarigliptin (MK-3102) CAS No：1226781-44-7 Eluxadoline CAS NO:864821-90-9 RU-58841 (also known as PSK-3841 or HMR-3841) CAS No：154992-24-2 Setipiprant CAS No：866460-33-5 CB-03-01 CAS No：19608-29-8 2-[1-BENZYL-4-PIPERIDYL]-2-PHENYLGLUTARIMIDE CAS No：5633-14-7 Saquinavir CAS No：149845-06-7 Sorafenib CAS No：284461-73-0 Hexachlorophene CAS No：70-30-4 Osimertinib mesylate CAS No：1421373-66-1 Mirabegron CAS No.:223673-61-8 Vortioxetine CAS No.:508233-74-7 Apremilast CAS No. 608141-41-9 Empagliflozin CAS No.864070-44-0 Palbociclib CAS NO.571190-30-2 bortezomib intermedate CAS NO.179324-87-9 CAS NO. 18680-27-8 bortezonib CAS NO 179324-69-7 Bleomycin Sulfate CAS NO.: 9041-93-4 Ethyl 2,2-difluoro-3-aminopropanoate hydrochloride CAS NO 541547-37-9 2-Bromo-5-hydroxypyrazine CAS NO 374063-92-0 2-Bromo-5-aminopyrazine CAS NO 59489-71-3 (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol CAS NO 877397-65-4 (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol CAS NO 330156-50-8 (S)-(-)-2-(Boc-amino)-1,4-butanediol CAS NO 128427-10-1 (R)-(+)-2-(Boc-amino)-1,4-butanediol CAS NO 397246-14-9 N-Boc-hexahydro-1H-azepin-4-one CAS NO 188975-88-4 (1R,4R)-4-(Boc-amino)cyclopent-2-enecarboxylic acid CAS NO 298716-03-7 (1S,2S)-(+)-Cyclohexane-1,2-diamine D-tartrate salt CAS NO 67333-70-4 (1R,2R)-(-)-Cyclohexane-1,2-diamine L-tartrate salt CAS NO 39961-95-0 1-Boc-3-(R )-aminopyrrolidine CAS NO 147081-49-0 3-Fluoro-1H-isoindoline hydrochloride CAS NO 924305-06-6 3-Bromo-1H-isoindoline hydrochloride CAS NO 923590-95-8 (1R,2S,3R,4S)-rel-1,7,7-Trimethylbicyclo[2.2.1]heptane-2,3-diol CAS NO 56614-57-4 Oxetan-3-ol CAS NO 7748-36-9 (S)-3-Aminotetrahydrofuran tosylate CAS NO 104530-79-2 (R)-3-Aminotetrahydrofuran tosylate CAS NO 111769-27-8 3-Oxocyclobutanecarboxylic acid CAS NO 23761-23-1 Sitagliptin Phosphate Intermediates CAS NO 12092-47-6 CAS NO 209995-38-0 CAS NO 762240-92-6 CAS NO 767340-03-4 CAS NO 486460-00-8 Vildagliptin Intermediates CAS NO 207557-35-5 Linagliptin Intermediates CAS NO 853029-57-9 CAS NO 666816-98-4 CAS NO 93703-24-3 CAS NO 109113-72-6 CAS NO 334618-23-4 CAS NO 309956-78-3 Saxagliptin Intermediates CAS NO 361442-00-4 CAS NO 361440-67-7 Bendamustine hydrochloride Intermediates CAS NO 3543-73-5 CAS NO 3543-74-6 Sofosbuvir Intermedaites CAS NO 1334513-02-8 CAS NO 863329-66-2 Ledipasvir Intermedaites CAS NO 1441670-89-8 CAS NO 1256387-87-7 Ivabradine hydrochloride Intermediates CAS NO 866783-13-3 CAS NO 35202-54-1 CAS NO 20925-64-8 CAS NO 73942-87-7 CAS NO 85175-59-3 CAS NO 148870-57-9 Temocapril hydrochloride Intermediates CAS NO 110221-26-6 CAS NO 88767-98-0 Dapagliflozin Intermediates CAS NO 461432-22-4 CAS NO 461432-23-5 CAS NO 461432-24-6 Canagliflozin Intermediates CAS NO 898566-17-1 CAS NO 1030825-20-7 Empagliflozin Intermediates CAS NO 915095-86-2 CAS NO 915095-87-3 CAS NO 915095-94-2 CAS NO 1279691-36-9 Ipragliflozin Intermediates CAS NO 1034305-21-9 CAS NO 1034305-17-3 Alogliptin Intermediates CAS NO 865758-96-9 Trelagliptin Intermediates CAS NO 4318-56-3 CAS NO 421552-12-7 Tasimelteon Intermediates CAS NO 230642-84-9 Silodosin Intermediates CAS NO 239463-85-5 CAS NO 160969-03-9 2-Diphenylmethylpiperidinehydrochloride CAS NO 5807-81-8 2,6-Dimethyl Hydroquinone CAS NO 654-42-2 2-Methyl-1-nitronaphthalene CAS NO 881-03-8 4-vinyl-2,3-dihydrobenzofuran CAS NO 230642-84-9 2,3-Dihydrobenzo[b]furan-5-carbaldehyde CAS NO 55745-70-5 2,3-Dihydro-1-benzofuran-5-propanoic acid CAS NO 215057-28-6 2-Pyrazinecarboxylic acid CAS NO 98-97-5 3-Amino-5-methylpyrazole CAS NO 31230-17-8 2-[2-(2-Thienyl)ethyl]benzoicacid CAS NO 1622-54-4 2-Ethoxycinnamic acid CAS NO 69038-81-9 Hexylamine CAS NO 111-26-2 1,1,3,3-Tetramethylguanidine CAS NO 80-70-6 Diethylamine hydrochloride CAS NO 660-68-4 2-Chloro-3,4-dimethoxybenzamide CAS NO 175136-02-4 2,3,4,6-Tetra-O-benzyl-D-galactopyranos CAS NO 53081-25-7 N-Methyl-N-[3-[3-(thien-2-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide CAS NO 325715-02-4 Dodecylamine CAS NO 124-22-1 Dipropylsulfide CAS NO 111-47-7 7-Methoxycoumarin CAS NO 531-59-9 2-Hexyne CAS NO 764-35-2 N-[2-(2-Acetamidophenyl)ethyl]-1-hydroxy-2-naphthamide CAS NO 5254-41-1 Methyl 4-Chloronicotinate CAS NO 63592-85-8 3-Chlorothiophene CAS NO 17249-80-8 4-Propoxycinnamic acid CAS NO 69033-81-4 4-Bromomethyltetrahydropyran CAS NO 125552-89-8 Methyl 3-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]benzoate CAS NO 781632-38-0 Di-tert-butyl azodicarboxylate CAS NO 870-50-8 Anthrone CAS NO 90-44-8 Methyl 2-(2-Furyl)benzoate CAS NO 39732-01-9 3-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 458532-92-8 benzyl 2,4-difluorophenylcarbamate CAS NO 112434-18-1 7-fluoro-1H-indazole-3-carboxylic acid CAS NO 959236-59-0 2-(2-bromo-6-nitrophenyl)ethanol CAS NO 118665-02-4 2,4-dichloropyridin-3-amine CAS NO 173772-63-9 2,2-dimethylpropanethioamide CAS NO 630-22-8 1-(2-amino-4-methylthiazol-5-yl)ethanone CAS NO 30748-47-1 2-(benzyloxy)-1-bromo-4-fluorobenzene CAS NO 202857-88-3 4-bromo-2-methoxyphenylboronic acid CAS NO 889849-21-2 3-BROMO-4-OXO-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER CAS NO 885278-03-5 (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate CAS NO 1268524-70-4 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 458532-88-2 [1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indol-4-yl]boronic acid CAS NO 1093066-72-8 1-(2-amino-4-methylthiazol-5-yl)ethanone CAS NO 30748-47-1 3-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 452972-13-3 benzyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylcarbamate CAS NO 1218790-11-4 tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate CAS NO 910462-31-6 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 1171891-31-8 2-methoxypyridin-3-ylboronic acid CAS NO 163105-90-6 5-methoxypyridin-3-ylboronic acid CAS NO 850991-69-4 2-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 214360-62-0 3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 458532-90-6 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 458532-84-8 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 719268-92-5 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine CAS NO 452972-14-4 2-[(3-CHLOROPROPYL)SULFANYL]PROPANENITRILE CAS NO 940315-21-9 3-cyano-2-hydroxybenzoic acid CAS NO 67127-84-8 1-isopropyl-1H-1,2,4-triazole CAS NO 63936-02-7 3-bromofuran-2-carboxylic acid CAS NO 14903-90-3 tert-butyl 2-carbamoylfuran-3-ylcarbamate CAS NO 655255-07-5 N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine CAS NO 904326-88-1 2-(dibenzo[b,d]furan-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane CAS NO 912824-85-2 4,4,5,5-tetramethyl-2-(furanyl-2-yl)-1,3,2-dioxaborolane CAS NO 374790-93-9 BOC-N-Methyl-L-alanine CAS NO 16948-16-6 pyridine-2,4-diol CAS NO 84719-31-3 tert-butyl 2-bromo-6-chloropyridin-3-ylcarbamate CAS NO 1227958-32-8 6-chloropyridin-2-amine CAS NO 45644-21-1 5-bromo-6-chloro-3-iodopyridin-2-amine CAS NO 1207625-23-7 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine CAS NO 944401-58-5 2-(dibenzo[b,d]thiophen-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane CAS NO 912824-84-1 2-(benzyloxy)-1-bromo-4-fluorobenzene CAS NO 202857-88-3 2-(benzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane CAS NO 94838-82-1 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline CAS NO 685103-98-4 4-benzylpiperidine hydrochloride CAS NO 31252-42-3 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine CAS NO 944401-58-5 5-bromo-4-(trifluoromethyl)pyrimidin-2-amine CAS NO 935534-47-7 benzyl 2,4-difluorophenylcarbamate CAS NO 112434-18-1 7-fluoro-1H-indazole-3-carboxylic acid CAS NO 959236-59-0 2-(2-bromo-6-nitrophenyl)ethanol CAS NO 118665-02-4 2,4-dichloropyridin-3-amine CAS NO 173772-63-9 2,2-dimethylpropanethioamide CAS NO 630-22-8 2-chloro-N-methoxy-N-methylacetamide CAS NO 67442-07-3 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)isoxazole CAS NO 832114-00-8

[yuking2020]

CAS:1535212-07-7

采购(14)

采购 Voxilaprevir 1535212-07-7 1.1g 请有现货/做过的小窗我 谢谢

[itsmedicinesfakianakis]

Monthly News Roundup - July 2017

FDA Approves Gilead’s Vosevi for Six Hepatitis C Genotypes The U.S. Food and Drug Administration (FDA) has approved Gilead’s Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for retreatment of adults with chronic hepatitis C virus (HCV) of… from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2va3ojm

from OtoRhinoLaryngology - Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tW0UW0

[expertofmarketinsights-blog]

Hepatitis C Drugs Market trend, outlook 2025

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, sexually or from infected mother to fetus. Globally, hepatitis C virus exists in six distinct forms based on its genotypes amongst which Type 1 is the most common form representing around 60 -70 per cent of global infections. Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1489

Hepatitis C drug market Driver

According to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C. This increasing prevalence of hepatitis C will drive growth of hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will further propel growth of hepatitis C drug market.

The governmental initiatives for patients to receive expanded drug coverage is also expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.

There are significant number of drugs available for Hepatitis C over the past few years and is expected to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline consists of dual as well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6. Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid patients.

Hepatitis C Drug Market

The major players in hepatitis C drug market include Merck & Co. Inc., Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb.

Ask for TOC : https://www.coherentmarketinsights.com/ongoing-insight/toc/1489

Hepatitis C drug market Taxonomy

By Drug Class

Hepatitis C Virus Protease Inhibitor

Glecaprevir

Grazoprevir

Paritaprevir

Simeprevir

Voxilaprevir

Nucleoside/tide Polymerase Inhibitors

Sofosbuvir

NS5A Inhibitors

Daclatasvir

Elbasvir

Ledipasvir

Ombitasvir

Pibrentasvir

Velpatasvir

Non-Nucleoside Polymerase Inhibitors

Dasabuvir

Interferon

Combinational drug

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: sales@coherentmarketinsights.com